financetom
Business
financetom
/
Business
/
ADM sees annual profit at lower end of prior range on macroeconomic uncertainty
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ADM sees annual profit at lower end of prior range on macroeconomic uncertainty
May 26, 2025 1:51 AM

(Reuters) -Grain trader Archer-Daniels-Midland ( ADM ) on Tuesday beat Wall Street expectations for first-quarter profit, but said it expects full-year adjusted earnings at the lower end of its previous forecast due to challenging macro-economic conditions.

Trade tensions between the U.S. and China are creating headwinds for ADM, which has seen its profit erode in recent quarters due to a slump in global crop prices and weak crop processing margins.

ADM relies on trade between top farm goods exporter the United States and China, the top importer.

It is also reeling from an accounting scandal last year that drew federal scrutiny and sent its stock price tumbling.

The company is responding to all these challenges through a cost-cutting and consolidation push. ADM said in February it planned to cut costs by $500 million to $750 million over the next three to five years and has been slashing jobs and downsizing operations since then.

ADM reaffirmed its full-year adjusted earnings forecast of $4 to $4.75 per share, but said it expects profit at the lower end of the range.

Strong performance at its Nutrition unit and lower costs helped the global grain merchant's first-quarter results.

The Chicago-based company posted an adjusted profit of 70 cents per share for the three months ended March 31, compared with analysts' average estimate of 67 cents, according to data compiled by LSEG.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Boeing May Be Beneficiary of All Nippon Airlines Expansion Plans
Market Chatter: Boeing May Be Beneficiary of All Nippon Airlines Expansion Plans
Jun 3, 2024
01:52 PM EDT, 06/03/2024 (MT Newswires) -- While Boeing ( BA ) still has to deliver more than 50 aircraft to All Nippon Airlines, it could still receive more orders from the Japanese carrier as it expands international flights, Bloomberg said Monday, citing All Nippon chief executive Shinichi Inoue. The report did not explicitly mention Boeing ( BA ) or...
US financial watchdog announces registry of nonbank corporate offenders
US financial watchdog announces registry of nonbank corporate offenders
Jun 3, 2024
(Reuters) - The U.S. consumer financial watchdog agency on Monday announced the creation of a public database to identify nonbank financial companies caught violating consumer laws, saying it would help catch and deter corporate repeat offenders. New regulations require debt collectors, mortgage and payday lenders, credit reporting companies and other nonbank financial services companies, many of which are not otherwise...
Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?
Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?
Jun 3, 2024
On Monday, Arrowhead Pharmaceuticals Inc ( ARWR ). released topline results from the Phase 3 PALISADE study of plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS). FCS  is a rare metabolic disease that prevents the body from digesting fats. Related: What Arrowhead Pharmaceutical’s Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder The...
Update: Intellia Therapeutics Shares Rise as NTLA-2002 Phase 1 Study Observes 98% Mean Reduction in Monthly Attack Rate
Update: Intellia Therapeutics Shares Rise as NTLA-2002 Phase 1 Study Observes 98% Mean Reduction in Monthly Attack Rate
Jun 3, 2024
01:56 PM EDT, 06/03/2024 (MT Newswires) -- (Updates with stock move in the headline and first paragraph.) Intellia Therapeutics' ( NTLA ) shares rose 10% in recent Monday afternoon trading after the company said it observed a 98% mean reduction in monthly attack rate in the phase 1 portion of its ongoing phase 1/2 study of NTLA-2002. The study is...
Copyright 2023-2026 - www.financetom.com All Rights Reserved